Reduced NF1 expression confers resistance to EGFR inhibition in lung cancer

Activating mutations in the EGF receptor (EGFR) are associated with clinical responsiveness to EGFR tyrosine kinase inhibitors (TKIs), such as erlotinib and gefitinib. However, resistance eventually arises, often due to a second EGFR mutation, most commonly T790M. Through a genome-wide siRNA screen...

Descripció completa

Guardat en:
Dades bibliogràfiques
Autors principals: de Bruin, Elza C., Cowell, Catherine, Warne, Patricia H., Jiang, Ming, Saunders, Rebecca E., Melnick, Mary Ann, Gettinger, Scott, Walther, Zenta, Wurtz, Anna, Heynen, Guus J., Heideman, Daniëlle A.M., Gómez-Román, Javier, García-Castaño, Almudena, Gong, Yixuan, Ladanyi, Marc, Varmus, Harold, Bernards, René, Smit, Egbert F., Politi, Katerina, Downward, Julian
Format: Artigo
Idioma:Inglês
Publicat: 2014
Matèries:
Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC4011693/
https://ncbi.nlm.nih.gov/pubmed/24535670
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/2159-8290.CD-13-0741
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars